A week af­ter up­dat­ing their S-1 in search of at least $115 mil­lion on the hot biotech IPO mar­ket, Po­sei­da Ther­a­peu­tics says it’s al­so raised a fresh ven­ture round — a lit­tle more than a year af­ter its last.

The first time around, af­ter Po­sei­da de­layed its IPO dur­ing a gov­ern­ment shut­down, the biotech re­port­ed a $150 mil­lion C round. This time around, it’s adding $110 mil­lion more from Fi­deli­ty Man­age­ment Re­search Com­pa­ny and oth­ers.

There’s no word in the biotech’s state­ment on No­var­tis, which bought up half of the eq­ui­ty for the Se­ries C cash with a $75 mil­lion in­vest­ment.

Ac­cord­ing to the SEC fil­ing, No­var­tis — which field­ed the first, some­what trou­bled CAR-T — owns 14.9% of the com­pa­ny, with Ma­lin in for 23.2%, though those num­bers may have changed now.

The big ben­e­fi­cia­ry is CEO Er­ic Os­tertag, who con­trols 12.6 mil­lion shares — 25.4% — through var­i­ous fam­i­ly trusts.

Po­sei­da’s big idea in­volves the use of a non-vi­ral DNA tech that they say can be used to gath­er a big­ger con­cen­tra­tion of stem cell mem­o­ry T cells that can avoid the ex­haus­tion that lim­its the ef­fi­ca­cy of the pi­o­neers — a cen­tral theme in cell ther­a­py 2.0.

Os­tertag picked up his PhD in mol­e­c­u­lar bi­ol­o­gy at Penn and went on to a ca­reer that in­clud­ed a va­ri­ety of biotech star­tups.

In the insular world of biotech, a spectacular failure can sometimes stay on any executive’s record for a long time. But for David Meek, the man at the helm of FerGene’s recent implosion, two questionable exits made way for what could be an excellent rebound.

Meek, most recently FerGene’s CEO and a past head at Ipsen, has become CEO at Mirati Therapeutics, taking the reins from founding CEO Charles Baum, who will step over into the role of president and head of R&D, according to a release.

The biotech industry has faced repeated calls to diversify its workforce — and in the last year, those calls got a lot louder. Though women account for just under half of all biotech employees around the world, they occupy very few places in C-suites, and even fewer make it to the helm.

Some companies are listening, according to a recent BIO survey which showed that this year’s companies were 2.5 times more likely to have a diversity and inclusion program compared to last year’s sample. But we still have a long way to go. Women represent just 31% of biotech executives, BIO reported. And those numbers are even more stark for women of color.

For a first-time fund, Jeito Capital talks a lot about continuity.

Rafaèle Tordjman had spotlighted that concept ever since she started building the firm in 2018, promising to go the extra mile(s) with biotech entrepreneurs while pushing them to reach patients faster.

Coincidentally, the lack of continuity was one of the sore spots listed in a report about the European healthcare sector published that same year by the European Investment Bank — whose fund is one of the LPs, alongside the American pension fund Teacher Retirement System of Texas and Singapore’s Temasek, to help Jeito close its first fund at $630 million (€534 million). As previously reported, Sanofi had chimed in €50 million, marking its first investment in a French life sciences fund.